Pamiparib is primarily used in the treatment of certain types of cancer, particularly those involving mutations in the BRCA1 and BRCA2 genes. It is a PARP inhibitor, which means it works by blocking the PARP enzymes that help repair damaged DNA in cancer cells. By inhibiting these enzymes, the drug prevents cancer cells from repairing their DNA, leading to their death. This makes it effective in treating ovarian, breast, and other cancers that are sensitive to PARP inhibition. It is often used in patients who have relapsed after prior treatments or those with specific genetic mutations. Pamiparib is also being studied in combination with other therapies, such as chemotherapy and immunotherapy, to enhance its effectiveness in targeting cancer cells. Its ability to selectively target cancer cells while sparing healthy ones makes it a promising option in oncology.